Synlogic, Inc.

NasdaqCM SYBX

Synlogic, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 7.60%

Synlogic, Inc. Gross Profit Margin is 7.60% for the Trailing 12 Months (TTM) ending September 30, 2024, a 101.14% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Synlogic, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -668.22%, a -5,047.80% change year over year.
Synlogic, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 13.51%, a 112.07% change year over year.
Synlogic, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 6.37%, a -93.63% change year over year.
Synlogic, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 100.00%, a 108.00% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: SYBX

Synlogic, Inc.

CEO	Mr. Antoine Awad
IPO Date	Sept. 30, 2015
Location	United States
Headquarters	301 Binney Street
Employees	6
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years